| Not Yet Recruiting | To Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of HRS-6209 in Subjects With HR-Positive/H Breast Cancer | Phase 1 | 2026-03-15 |
| Recruiting | A Trial of SHR-2173 in Healthy Volunteers Immunology | Phase 1 | 2026-03-06 |
| Recruiting | A Trial of HRS-5817 in Obese Participants Obesity | EARLY_Phase 1 | 2026-01-05 |
| Active Not Recruiting | A Trial of SHR-1139 in Healthy Volunteers Psoriasis | Phase 1 | 2025-08-19 |
| Completed | A Trial of HRS-1893 in Healthy Volunteers Hypertrophic Cardiomyopathy | EARLY_Phase 1 | 2025-06-25 |
| Recruiting | A Trial of HRS-5041-103 to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of HRS-5041 in Sub Metastatic Castration Resistant Prostate Cancer | Phase 1 | 2025-06-15 |
| Withdrawn | A Trial of SHR-4602 Infusion in Patients With SHR-4602 in Subjects With HER2-expressing or HER2-mutated Locall HER2-expressing or HER2-mutated Locally or Metastatic Solid Tumors | Phase 1 | 2025-03-01 |
| Completed | Phase 1 Study to Evaluate PK, Safety, and Tolerability of HRS-5041 in Healthy Caucasian Male Participants Prostate Cancer | Phase 1 | 2024-09-25 |
| Completed | Phase 1 Study of HRS-9231 Safety and Pharmacokinetics in Healthy Caucasians MRI | EARLY_Phase 1 | 2024-08-21 |
| Completed | A Trial of SHR-1707 Infusion in Patients With Mild Cognitive Impairment Due to Alzheimer's Disease and Mild Al Alzheimer's Disease (AD) | Phase 1 | 2024-04-17 |
| Completed | A Trial of HRS-7085 Tablet in Healthy Participants With and Without Food Effect. Inflammatory Bowel Disease | Phase 1 | 2022-12-05 |
| Completed | A Trial of SHR-A1921 for Injection in Subjects With Advanced Solid Tumors Advanced Solid Tumor | Phase 1 | 2022-12-01 |
| Completed | Phase I Study of SHR-2002 + SHR-1316 in Patients With Advanced Malignant Tumors Advanced Malignant Tumors | Phase 1 | 2021-11-23 |
| Completed | A Trial of SHR-1905 in Healthy Subjects Asthma | Phase 1 | 2021-07-27 |
| Terminated | A Trial of SHR-1703 in Healthy Subjects Asthma | Phase 1 | 2021-06-14 |
| Completed | A Trial of SHR2285 in Healthy Subjects Healthy Volunteers | Phase 1 | 2021-05-20 |
| Completed | A Trial of SHR-1707 in Healthy Young Adult and Elderly Subjects Alzheimer Disease | Phase 1 | 2021-02-23 |
| Completed | A Trial of SHR8735 in Healthy Subjects Healthy Volunteers | Phase 1 | 2021-02-11 |
| Completed | A Trial of HRS4800 Tables in Healthy Male Subjects Pain | Phase 1 | 2020-11-12 |
| Completed | A Trial of SHR-1819 in Healthy Subjects Healthy Volunteers | Phase 1 | 2020-11-01 |
| Completed | A Trial of SHR3162 in Healthy Caucasian Volunteers Healthy Volunteers | Phase 1 | 2020-04-17 |
| Completed | A Trial of SHR-1701 in Subjects With Advanced Solid Tumors Advanced Solid Tumor | Phase 1 | 2020-03-31 |
| Completed | A Trial of SHR6390 in Healthy Caucasian Volunteers Healthy Volunteers | Phase 1 | 2020-03-12 |
| Completed | A Trial of SHR0410 Injection in Hemodialysis Participants. Pruritus | Phase 1 | 2019-04-15 |
| Completed | A Single Dose Study of SHR0410 in Healthy Male Participants Acute Pain | Phase 1 | 2018-04-15 |
| Completed | A Trial of HTI-1090 in Subjects With Advanced Solid Tumors Advanced Solid Tumors | Phase 1 | 2017-08-30 |
| Completed | Multiple Doses Study of SHR4640 in Male Subjects With High Serum Uric Acid Level Gout, Hyperuricemia | Phase 1 | 2017-07-04 |
| Completed | A Trial to Evaluate Safety and Tolerability of SHR-1316 in Cancer Patients Advanced Solid Tumors | Phase 1 | 2017-06-01 |
| Completed | A Single Dose Study of SHR4640 in Healthy Male Volunteers Gout | Phase 1 | 2016-09-22 |
| Completed | A Phase I Trial of HS-10241 in Solid Tumors Neoplasm, Solid Tumors | Phase 1 | 2016-09-01 |
| Completed | A Phase 1 Trial of SHR3680 With or Without SHR3162 in Prostate Cancer Neoplasm, Prostate Cancer | Phase 1 | 2016-09-01 |
| Completed | A Study of SHR-1314 in Healthy Subjects Psoriasis | Phase 1 | 2016-08-22 |
| Completed | A Phase I Trial of SHR3162 in Subjects With Advanced Solid Tumors Neoplasm, Solid Tumors | Phase 1 | 2016-06-01 |
| Completed | A Trial to Evaluate Safety and Tolerability of INCSHR01210 in Cancer Patients Solid Tumors and Hematologic Malignancy | Phase 1 | 2015-09-01 |